Rezolute: Wedbush Raises Price Target After upLIFT Study Data - Experts See 173% Price Potential!
Reading Time: 2 minutes
Wedbush sets a price target for Rezolute (RZLT) at 10 USD after positive Phase 3 data for Ersodetug. Rezolute addresses a potential market volume of 5 billion USD with its antibody. A Biologics License Application (BLA) for one or both indications is planned for 2027. Focus on Rare Metabolic Disorders and Antibody Therapies The business model of Rezolute (RZLT) focuses on therapies for rare metabolic disorders, primarily for refractory hypoglycemia due to hyperinsulinism (HI). The main candidate, Ersodetug, a monoclonal antibody,...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.

